

## **Transparency and Honesty**

At Thornton & Ross Limited (T&R), we firmly believe that transparency and honesty are essential in maintaining trust and confidence in the pharmaceutical industry.

Below is the Methodological Note outlining our approach to the collection and submission of all Transfers of Value (ToVs) to Patient Organisations and members of the public, as mandated by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice.

### **Methodological Note**

The types of ToVs included are:

- Sponsorships and payments made for the provision of contracted services paid to Patient Organisations.
- Sponsorships of events and charity grants paid to non-UK based Healthcare Organisations.
- Payments made in connection with the provision of contracted services paid to members of the public, including patients.

UK payments made to UK Healthcare Professionals and UK Healthcare Organisations can be found using [this link](#).

### **Reporting period and dates**

Disclosures are made annually in respect of each calendar year, from 1st January until 31st December in each year. ToVs are disclosed in the year the payments are made.

### **Currency**

All payments disclosed are in the currency in which the payment was made in. i.e. Euros and Great British Pound (GBP)

### **Data collection**

We rigorously review financial data for each year regarding our qualifying ToVs made to Patient Organisations and members of the public. This data is cross-referenced against records maintained by our medical and commercial teams that document all completed engagements with these entities.

No indirect ToVs have been made to Patient Organisations, non-UK based Healthcare Organisations and members of the public.

For members of the public, disclosures are aggregated into patients. Disclosure is not made against individuals.

**2025 – Payments to Patient Organisations:**

<b>Country</b>	<b>Name of Organisation</b>	<b>Description of Support</b>	<b>Amount</b>	<b>Nature of Support</b>
England	XXXXXXX*	Licensing agreement	£55,000	Financial
England	Kidneys for Life	Sponsorship	£12,000	Financial
England	Kidneys for Life	Grant	£50,000	Financial

\*Name redacted due to contractual confidentiality clauses.

**2025 – Payments to Members of the Public:**

<b>Country</b>	<b>Number of individuals paid</b>	<b>Amount</b>	<b>Description of Support</b>	<b>Nature of Support</b>
England	2	£356.65	Expenses in connection with attendance at a speaker event	Financial (Expenses)